Découvrez ce produit en action.
case study
An observational case series study evaluating the clinical effects of the Alteco LPS Adsorber in patients with vasopressor-dependent septic shock, demonstrating reduced endotoxin activity, SOFA scores, and vasopressor requirements.
case study
A retrospective observational study evaluating the efficacy of the Alteco LPS Adsorber in patients undergoing surgery for Type A Acute Aortic Dissection. The study demonstrates that early use of the device during cardiopulmonary bypass and in the ICU significantly reduces endotoxin levels and serum lactate, improving tissue perfusion within 72 hours post-surgery.
case study
A clinical case report detailing the use of the Alteco LPS Adsorber in a 58-year-old male patient with septic shock caused by E. Coli pyelonephritis. The treatment, combined with CVVHDF, resulted in improved hemodynamic and respiratory parameters, reduced vasopressor requirements, and no adverse events.
ifu
Instructions for use for the Alteco LPS Adsorber, an extracorporeal device designed to remove endotoxins from the bloodstream in patients with sepsis or septic shock.
clinical study
A compilation of clinical studies, case reports, and observational data evaluating the safety and efficacy of the Alteco LPS Adsorber in treating patients with septic shock, severe sepsis, and during cardiac surgery. The studies consistently demonstrate effective endotoxin elimination, improved hemodynamic parameters, reduced SOFA scores, and favorable clinical outcomes.
case study
A clinical case report detailing the successful use of the Alteco LPS Adsorber for endotoxin removal in a 29-year-old patient suffering from severe ARDS, septic shock, and bacterial coinfection at the Medical University Hospital in Wroclaw, Poland.
clinical study
An observational cohort study of 64 patients in Poland evaluating the effectiveness of the Alteco LPS Adsorber in patients with septic shock and endotoxemia, demonstrating reduced endotoxin activity, improved organ function, and decreased SOFA scores.
certificate iso
ISO 13485:2016 quality management system certificate issued to Alteco Medical AB for the design, manufacture, and distribution of products for extracorporeal blood treatment.
certificate ce
Full Quality Assurance System Certificate for Alteco Medical AB, covering the design, production, and marketing of the Alteco LPS Adsorber medical device under Council Directive 93/42/EEC.
ifu
Instructions for use for the Alteco LPS Adsorber, a device for extracorporeal treatment of endotoxemia, sepsis, or septic shock caused by Gram-negative bacteria. Includes preparation, priming, and treatment procedures.
ifu
Instructions for use for the Alteco LPS Adsorber, covering description, indications, contraindications, precautions, and procedural steps for extracorporeal treatment of endotoxemia and sepsis.
ifu
Instructions for use for the Alteco LPS Adsorber (Model LPS-33-100-46), an extracorporeal device designed to remove endotoxins (LPS) from the blood of patients with endotoxemia, sepsis, or septic shock caused by gram-negative bacteria.
ifu
Instructions for use for the Alteco LPS Adsorber (model LPS-33-100-46), an extracorporeal hemadsorption device designed to remove endotoxins from the blood of patients with endotoxemia, sepsis, or septic shock caused by Gram-negative bacteria.
ifu
Instructions for use for the Alteco LPS Adsorber, a device for extracorporeal therapy designed to treat endotoxemia, sepsis, or septic shock caused by gram-negative bacteria. Includes preparation, priming, and treatment procedures.
ifu
Instructions for use for the Alteco LPS Adsorber, covering device description, indications for endotoxemia treatment, contraindications, precautions for patients under 30kg, and operational procedures including rinsing and preparation.
Alteco Medical AB
Contactez directement Alteco Medical AB pour demander les prix, des échantillons et les délais de livraison pour Alteco LPS Adsorber.
The Alteco LPS Adsorber is an add-on extracorporeal therapy designed to treat endotoxemia in sepsis patients. By utilizing a synthetic peptide to bind and remove endotoxin from the bloodstream, it helps break the chain of immune system overreactions and supports hemodynamic stabilization in acute clinical situations.
| Usage | Single-Use |
|---|---|
| Adsorption Surface Area | 4 m2 |
| Pore Size | 100 microns |
| Recommended Blood Flow Rate | 150 ± 50 ml/min |
| Treatment Time | 2-6 hours |
